IT201900004877A1 - PROCESS OF PREPARATION OF CONCENTRATED COLLOIDAL SYSTEMS - Google Patents
PROCESS OF PREPARATION OF CONCENTRATED COLLOIDAL SYSTEMS Download PDFInfo
- Publication number
- IT201900004877A1 IT201900004877A1 IT102019000004877A IT201900004877A IT201900004877A1 IT 201900004877 A1 IT201900004877 A1 IT 201900004877A1 IT 102019000004877 A IT102019000004877 A IT 102019000004877A IT 201900004877 A IT201900004877 A IT 201900004877A IT 201900004877 A1 IT201900004877 A1 IT 201900004877A1
- Authority
- IT
- Italy
- Prior art keywords
- phase
- water
- process according
- hydrophilic
- colloidal systems
- Prior art date
Links
- 239000000084 colloidal system Substances 0.000 title claims description 20
- 238000000034 method Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 5
- 239000012071 phase Substances 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 108010013296 Sericins Proteins 0.000 claims description 6
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 108010022355 Fibroins Proteins 0.000 claims description 4
- 150000002334 glycols Chemical class 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 2
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 2
- FVKRIDSRWFEQME-UHFFFAOYSA-N 3-methylbutyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCC(C)C FVKRIDSRWFEQME-UHFFFAOYSA-N 0.000 claims description 2
- 235000019493 Macadamia oil Nutrition 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims description 2
- 235000019868 cocoa butter Nutrition 0.000 claims description 2
- 229940110456 cocoa butter Drugs 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 claims description 2
- 229940078565 isoamyl laurate Drugs 0.000 claims description 2
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 2
- 239000010469 macadamia oil Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 229940057910 shea butter Drugs 0.000 claims description 2
- 229950004959 sorbitan oleate Drugs 0.000 claims description 2
- 229950011392 sorbitan stearate Drugs 0.000 claims description 2
- 241000221095 Simmondsia Species 0.000 claims 1
- 235000004433 Simmondsia californica Nutrition 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- -1 jojoba oil Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0291—Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Descrizione del brevetto per invenzione industriale avente per titolo: Description of the patent for industrial invention entitled:
“PROCESSO DI PREPARAZIONE DI SISTEMI COLLOIDALI CONCENTRATI” "PROCESS OF PREPARATION OF CONCENTRATED COLLOIDAL SYSTEMS"
La presente invenzione ha per oggetto un processo di preparazione di sistemi colloidali concentrati, che - una volta diluiti in acqua - danno origine a emulsioni istantanee stabili. Queste emulsioni, da sole o arricchite da altri ingredienti, sono utili in campo dermatologico e cosmetico. The present invention relates to a process for preparing concentrated colloidal systems which - once diluted in water - give rise to instant stable emulsions. These emulsions, alone or enriched with other ingredients, are useful in the dermatological and cosmetic fields.
Sfondo dell’invenzione Background of the invention
I sistemi colloidali sono costituiti da sostanze che si trovano in uno stato finemente disperso, con dimensioni delle particelle comprese tra 10<-9 >e10<-6 >m (a metà tra le soluzioni vere, <10<-9>, e le dispersioni eterogenee, >10<-6>). Colloidal systems consist of substances that are in a finely dispersed state, with particle sizes between 10 <-9> and 10 <-6> m (halfway between true solutions, <10 <-9>, and heterogeneous dispersions,> 10 <-6>).
Le particelle colloidali sono soggette ai moti browniani (rapidi e continui movimenti), mentre le particelle delle sospensioni eterogenee sono soggette soltanto ai moti convettivi e gravitazionali. Colloidal particles are subject to Brownian motions (rapid and continuous movements), while particles of heterogeneous suspensions are subject only to convective and gravitational motions.
Spesso la fase dispersa assume strutture di organizzazione supramolecolare di tipo micellare. Often the dispersed phase takes on supramolecular organization structures of the micellar type.
Una delle proprietà caratteristiche che serve a distinguere i sistemi colloidali dalle soluzioni è l'effetto Tyndall: quando un raggio di luce attraversa un liquido puro o una soluzione, questa non viene diffusa lateralmente perché le particelle in soluzione sono troppo piccole, mentre nei sistemi colloidali le dimensioni delle particelle sono in grado di diffonderla, dando origine all’opalescenza o addirittura all’aspetto torbido. One of the characteristic properties that serves to distinguish colloidal systems from solutions is the Tyndall effect: when a ray of light passes through a pure liquid or a solution, it is not scattered laterally because the particles in solution are too small, while in colloidal systems the size of the particles are able to diffuse it, giving rise to opalescence or even a cloudy appearance.
I sistemi colloidali disperdibili sono da tempo utilizzati come veicoli di sostanze biologicamente attive quali farmaci, agenti cosmetici, proteine, enzimi. Dispersible colloidal systems have long been used as vehicles for biologically active substances such as drugs, cosmetic agents, proteins, enzymes.
La preparazione e l’impiego di tali sistemi sono descritti in numerosi brevetti e pubblicazioni. Si veda ad esempio EP 349429, EP 2266546 ed EP 2405896. The preparation and use of these systems are described in numerous patents and publications. See for example EP 349429, EP 2266546 and EP 2405896.
Data la complessità dei sistemi colloidali, variazioni nel loro processo di preparazione possono determinare significative modifiche alle caratteristiche applicative e funzionali dei sistemi colloidali stessi. Given the complexity of colloidal systems, variations in their preparation process can determine significant changes to the application and functional characteristics of the colloidal systems themselves.
Descrizione dell’invenzione Description of the invention
Si è ora trovato che utilizzando una fase idrofila con basso contenuto di acqua in combinazione con una fase lipofila e fosfolipidi è possibile ottenere in modo vantaggioso sistemi colloidali concentrati che, diluiti in acqua, a freddo e senza consumo di energia, danno origine a emulsioni istantanee e particolarmente stabili con dimensioni delle particelle nell’ordine dei nanometri (50 - 500 nm). I sistemi colloidali così ottenuti stabilizzano le emulsioni/formulazioni cosmetiche e sono facilmente disperdibili in forma di gel a base di acrilati o metacrilati. It has now been found that by using a hydrophilic phase with low water content in combination with a lipophilic phase and phospholipids it is possible to advantageously obtain concentrated colloidal systems which, diluted in water, cold and without energy consumption, give rise to instant emulsions. and particularly stable with particle sizes in the nanometer range (50 - 500 nm). The colloidal systems thus obtained stabilize the emulsions / cosmetic formulations and are easily dispersible in the form of acrylate or methacrylate-based gel.
Detti sistemi colloidali sono ottenibili secondo l’invenzione per miscelazione di una fase lipofila, una componente fosfolipidica e una fase idrofila comprendente glicerina, acqua ed eventualmente proteine e glicoli, la percentuale in peso dell’acqua sul totale della fase idrofila essendo compresa tra il 10 e il 20%. Preferibilmente, la fase acquosa è costituita da una miscela di glicerina:acqua in rapporti in peso compresi tra 90:10 e 80:20. Said colloidal systems can be obtained according to the invention by mixing a lipophilic phase, a phospholipidic component and a hydrophilic phase comprising glycerin, water and optionally proteins and glycols, the percentage by weight of water on the total of the hydrophilic phase being between 10 and 20%. Preferably, the aqueous phase consists of a glycerin: water mixture in weight ratios ranging from 90:10 to 80:20.
La fase lipofila comprende uno o più componenti scelti fra trigliceride caprilico/caprico, octil palmitato, decil oleato, sorbitan oleato e stearato, isononil isononanoato, isoamil laurato, ottildodecanolo, dicaprilil etere, ceramidi, olio di jojoba, olio di cocco, olio di macadamia, burro di karitè, burro di cacao. The lipophilic phase comprises one or more components selected from caprylic / capric triglyceride, octyl palmitate, decyl oleate, sorbitan oleate and stearate, isononyl isononanoate, isoamyl laurate, octyldodecanol, dicaprilyl ether, ceramides, jojoba oil, coconut oil, macadamia oil , shea butter, cocoa butter.
I fosfolipidi sono scelti fra lecitina, lecitina idrogenata o fosfatidilcolina. Alla fase idrofila possono essere aggiunti glicoli e/o composti attivi per applicazioni cosmetiche, farmaceutiche o dermatologiche. In particolare, si possono ottenere sistemi colloidali e liposomiali utili in cosmetica contenenti nella fase idrofila proteine quali sericina o fibroina. The phospholipids are selected from lecithin, hydrogenated lecithin or phosphatidylcholine. Glycols and / or active compounds for cosmetic, pharmaceutical or dermatological applications can be added to the hydrophilic phase. In particular, colloidal and liposomal systems useful in cosmetics can be obtained containing proteins such as sericin or fibroin in the hydrophilic phase.
Secondo il processo dell’invenzione, si prepara una fase A lipofila miscelando gli ingredienti lipofili, scaldando a 40 - 50°C sotto agitazione. A questa fase viene aggiunta la componente fosfolipidica omogeneizzata fino a scomparsa di eventuali aggregati. According to the process of the invention, a lipophilic phase A is prepared by mixing the lipophilic ingredients, heating to 40 - 50 ° C under stirring. The homogenized phospholipid component is added to this phase until any aggregates disappear.
Si prepara quindi la fase idrofila B miscelando sotto agitazione glicerina, acqua ed eventualmente glicoli e si aggiunge quindi la fase B alla fase A lasciando in agitazione fino a completa dispersione. The hydrophilic phase B is then prepared by mixing glycerin, water and possibly glycols under stirring and then phase B is added to phase A, stirring until complete dispersion.
Se desiderato, si aggiungono le proteine (sericina, fibroina) o altri ingredienti attivi e si riscalda fino a 60 - 70°C per poi omogeneizzare sotto vuoto. If desired, proteins (sericin, fibroin) or other active ingredients are added and it is heated up to 60 - 70 ° C and then homogenized under vacuum.
Si effettuano un trattamento in omogeneizzatore ad alta pressione. A high pressure homogenizer treatment is carried out.
Nella forma concentrata così ottenuta, il sistema è organizzato in forma micellare con un core oleoso e una fase dispersa idrofila. Nel momento in cui il sistema viene diluito in acqua si verifica una riorganizzazione della struttura in forma liposomiale (principalmente small unilamellar vescicles - SUV - ma anche median e large unilamellar vescicles - MUV e LUV -, multilamellar vescicles - MLV - e multivescicular - MVV). In the concentrated form thus obtained, the system is organized in micellar form with an oily core and a hydrophilic dispersed phase. When the system is diluted in water, a reorganization of the structure in liposomal form occurs (mainly small unilamellar vescicles - SUV - but also median and large unilamellar vescicles - MUV and LUV -, multilamellar vescicles - MLV - and multivescicular - MVV) .
Questa riorganizzazione avviene spontaneamente senza che vi sia necessità di somministrare energia meccanica o termica. This reorganization occurs spontaneously without the need to administer mechanical or thermal energy.
I sistemi liposomiali ottenuti possono essere formulati in sospensioni, creme, gel, schiume, lozioni eventualmente in combinazione con ingredienti ed eccipienti convenzionali nel settore cosmetico, ad esempio oli, additivi reologici, tensioattivi, umettanti, emollienti, profumi, filtri solari, etc. The liposomal systems obtained can be formulated in suspensions, creams, gels, foams, lotions possibly in combination with conventional ingredients and excipients in the cosmetic sector, for example oils, rheological additives, surfactants, humectants, emollients, perfumes, sun filters, etc.
Gli esempi seguenti illustrano ulteriormente l’invenzione. The following examples further illustrate the invention.
Esempio 1 Example 1
Si prepara una fase A in cui viene scaldato il trigliceride caprilico/caprico (10 – 25% in peso sul totale del sistema colloidale) a 45°C sotto agitazione. Ad esso si aggiunge lecitina (2 - 10% in peso sul totale del sistema colloidale) e si turboemulsiona sotto vuoto. A phase A is prepared in which the caprylic / capric triglyceride (10 - 25% by weight of the total colloidal system) is heated to 45 ° C under stirring. To it is added lecithin (2 - 10% by weight of the total colloidal system) and it is turboemulsified under vacuum.
Si prepara la fase B miscelando glicerina (90 - 80% in peso) e acqua (10 - 20% in peso). Phase B is prepared by mixing glycerin (90 - 80% by weight) and water (10 - 20% by weight).
Si aggiunge la fase B alla fase A e si lascia in agitazione fino a completa dispersione. Phase B is added to phase A and the mixture is left under stirring until complete dispersion.
A questo punto si aggiunge sericina (0,5 - 5% in peso sul totale del sistema colloidale) e si riscalda fino a 60 - 70°C per poi turboemulsionare a questa temperatura sotto vuoto. At this point, sericin is added (0.5 - 5% by weight of the total colloidal system) and it is heated up to 60 - 70 ° C and then turboemulsified at this temperature under vacuum.
Il prodotto viene quindi omogeneizzato ad alta pressione. The product is then homogenized under high pressure.
Esempio 2 Example 2
Si prepara una fase A in cui viene scaldato l’octil palmitato (10 - 25% in peso sul totale del sistema colloidale) a 45°C sotto agitazione. Ad esso si aggiunge lecitina idrogenata (2 - 10% in peso sul totale del sistema colloidale) e si turboemulsiona a sotto vuoto. A phase A is prepared in which the octyl palmitate (10 - 25% by weight of the total colloidal system) is heated to 45 ° C under stirring. To it is added hydrogenated lecithin (2 - 10% by weight of the total colloidal system) and it is turboemulsified under vacuum.
Si prepara la fase B miscelando glicerina (80-90% in peso) e acqua (10 - 20% in peso). Phase B is prepared by mixing glycerin (80-90% by weight) and water (10 - 20% by weight).
Si aggiunge la fase B alla fase A e si lascia in agitazione fino a completa dispersione. Phase B is added to phase A and the mixture is left under stirring until complete dispersion.
A questo punto si aggiunge sericina (0,5 - 5% in peso sul totale del sistema colloidale) e si riscalda fino a 60 - 70°C per poi turboemulsionare a questa temperatura sotto vuoto. At this point, sericin is added (0.5 - 5% by weight of the total colloidal system) and it is heated up to 60 - 70 ° C and then turboemulsified at this temperature under vacuum.
Il prodotto viene quindi omogeneizzato ad alta pressione. The product is then homogenized under high pressure.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102019000004877A IT201900004877A1 (en) | 2019-04-01 | 2019-04-01 | PROCESS OF PREPARATION OF CONCENTRATED COLLOIDAL SYSTEMS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102019000004877A IT201900004877A1 (en) | 2019-04-01 | 2019-04-01 | PROCESS OF PREPARATION OF CONCENTRATED COLLOIDAL SYSTEMS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT201900004877A1 true IT201900004877A1 (en) | 2020-10-01 |
Family
ID=67262828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102019000004877A IT201900004877A1 (en) | 2019-04-01 | 2019-04-01 | PROCESS OF PREPARATION OF CONCENTRATED COLLOIDAL SYSTEMS |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT201900004877A1 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0349429A2 (en) | 1988-06-30 | 1990-01-03 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of submicronic liposomes |
| WO2001025223A1 (en) * | 1999-10-06 | 2001-04-12 | The Research Foundation Of State University Of New York | Stabilization of taxane-containing dispersed systems |
| US20100189662A1 (en) * | 2007-06-19 | 2010-07-29 | Neubourg Skin Care Gmbh & Co. Kg | DMS (derma membrane structure) in Foam Creams |
| EP2266546A1 (en) | 2009-06-08 | 2010-12-29 | Advancell Advanced in Vitro Cell Technologies,S.A. | Process for the preparation of colloidal systems for the delivery of active compounds |
| EP2405896A1 (en) | 2009-03-10 | 2012-01-18 | Prigen S.r.l. | Glycerosomes and use thereof in pharmaceutical and cosmetic preparations for topical application |
| WO2018020903A1 (en) * | 2016-07-29 | 2018-02-01 | セーレン株式会社 | External agent for skin |
| EP3338759A1 (en) * | 2016-11-22 | 2018-06-27 | CMS Lab Inc. | Vesicles containing saccharide isomerate, hydrolyzed lupine protein, and intercorneocyte lipid mimetics as active ingredient, and composition for skin external application comprising the same |
| EP3381517A1 (en) * | 2017-03-29 | 2018-10-03 | Universita' Degli Studi Di Cagliari | Phospholipid three-dimensional vesicular aggregates scattered in alcoholic mixtures with no or low water content, their preparation and use in formulations for topical application |
-
2019
- 2019-04-01 IT IT102019000004877A patent/IT201900004877A1/en unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0349429A2 (en) | 1988-06-30 | 1990-01-03 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of submicronic liposomes |
| WO2001025223A1 (en) * | 1999-10-06 | 2001-04-12 | The Research Foundation Of State University Of New York | Stabilization of taxane-containing dispersed systems |
| US20100189662A1 (en) * | 2007-06-19 | 2010-07-29 | Neubourg Skin Care Gmbh & Co. Kg | DMS (derma membrane structure) in Foam Creams |
| EP2405896A1 (en) | 2009-03-10 | 2012-01-18 | Prigen S.r.l. | Glycerosomes and use thereof in pharmaceutical and cosmetic preparations for topical application |
| EP2266546A1 (en) | 2009-06-08 | 2010-12-29 | Advancell Advanced in Vitro Cell Technologies,S.A. | Process for the preparation of colloidal systems for the delivery of active compounds |
| WO2018020903A1 (en) * | 2016-07-29 | 2018-02-01 | セーレン株式会社 | External agent for skin |
| EP3338759A1 (en) * | 2016-11-22 | 2018-06-27 | CMS Lab Inc. | Vesicles containing saccharide isomerate, hydrolyzed lupine protein, and intercorneocyte lipid mimetics as active ingredient, and composition for skin external application comprising the same |
| EP3381517A1 (en) * | 2017-03-29 | 2018-10-03 | Universita' Degli Studi Di Cagliari | Phospholipid three-dimensional vesicular aggregates scattered in alcoholic mixtures with no or low water content, their preparation and use in formulations for topical application |
Non-Patent Citations (1)
| Title |
|---|
| MANCA MARIA LETIZIA ET AL: "Improvement of quercetin protective effect against oxidative stress skin damages by incorporation in nanovesicles", COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM, NL, vol. 123, 7 October 2014 (2014-10-07), pages 566 - 574, XP029106641, ISSN: 0927-7765, DOI: 10.1016/J.COLSURFB.2014.09.059 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2369912T3 (en) | TRANSLUCED NANOEMULSION, ITS MANUFACTURING PROCEDURE AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL AREAS. | |
| ES2296218T5 (en) | COMPOSITION OF REVERSE EMULSION TYPE CONTAINING CALCITRIOL AND 17-CLOBETASOL PROPIONATE AND ITS USE IN COSMETICS AND DERMATOLOGY. | |
| US20170231909A1 (en) | Foam prepared from nanoemulsions and uses | |
| EP2363108B1 (en) | Foam formulation containing at least one triterpenoid | |
| JP4040527B2 (en) | Lipid composition and external preparation for skin containing the same | |
| JP2002020236A (en) | Composition for make-up and/or make-up care in powdery form and containing specific binder | |
| CN105934239A (en) | Lipid microcapsules preferably comprising a lipophilic active substance and composition containing same, method for the production thereof, and use of same in dermatology and in cosmetics | |
| JP2000026273A (en) | Composition for make-up or dermatological use in form of oil phase and aqueous phase dispersion stabilized by using cubic gel particle | |
| JP2013241469A (en) | Composition containing benzoyl peroxide, at least one kind of naphthoic acid derivative, and at least one kind of polyurethane polymer compound or derivative thereof, and use thereof | |
| JP6339376B2 (en) | Cosmetics | |
| ES2613387T3 (en) | Improved administration of skin benefit agents | |
| CN106132388A (en) | Oil-in-water emulsion type cosmetic preparation | |
| Mitrea et al. | New approaches on the synthesis of effective nanostructured lipid carriers | |
| KR20180106106A (en) | Oil-in-water emulsion cosmetic composition improving deviation of emulsion particle size, and preparing method for the same | |
| JP2020186227A (en) | Oil-in-water type emulsion composition | |
| KR101503301B1 (en) | Retinylpalmitate stabilized formulations | |
| JP2004331594A (en) | Preparation having liquid crystal structure | |
| JP7211818B2 (en) | Skin topical agent | |
| IT201900004877A1 (en) | PROCESS OF PREPARATION OF CONCENTRATED COLLOIDAL SYSTEMS | |
| JP6900002B2 (en) | Liquid crystal mixed crystal emulsified composition, liquid crystal emulsified cosmetic, liquid crystal mixed crystal emulsified composition manufacturing method and liquid crystal emulsified cosmetic manufacturing method | |
| US6960354B1 (en) | Membrane lipid compositions | |
| KR100570497B1 (en) | Anti-wrinkle cosmetic composition and its manufacturing method containing a pure retinol stabilized with a nano size of multiple liquid crystal membrane capsule | |
| KR100501728B1 (en) | Cosmetic composition having the capsule structure of multiple-liquid crystalline membrane with nano size and manufacturing method thereof | |
| WO2014103742A1 (en) | Reverse vesicle composition and method for producing same | |
| KR102199766B1 (en) | Manufacturing method of multi-lamellar structured transparent liquid crystal composition |